Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
In this video, Adrian Towse discusses the challenges and importance of appropriately valuing genomic medicine. He addresses both gene therapies and “pharmacogenomics” — those medicines that…
Valuing Orphan Medicines Using Multi-Criteria Decision Analysis
7 May 2013
OHE has just released a research paper that describes an experimental study intended to test whether and how a multi-criteria decision analysis (MCDA) approach can be…
NICE Decisions: Exploring the Influence of Cost-Effectiveness and Other Factors
30 April 2013
OHE presents a series of lunchtime seminars throughout the year. The most recent seminar, held in late April, considered the influence of cost-effectiveness and other factors…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
Advances in science and technology are producing more and better means for diagnosing disease, matching patients to the best therapies, and tracking the progress of treatment.…
Performance-Based Risk Sharing in Health Care: Current Status
17 April 2013
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on…
Lunchtime Seminar: Capturing Preferences about Treatment at the End of Life
9 April 2013
OHE’s Koonal Shah is a co-investigator in research intended to define public preferences about allocating health care resources to patients who are at the end of…
OHE Presents at Two Key Workshops on Use of EQ-5D in HTA Across Asia
27 March 2013
OHE’s Prof Nancy Devlin presented at two key workshops held for researchers and HTA policy makers from across Asia. The workshops were organised by Prof Nan…
Review of Plans for Refining Patient-Reported Outcomes Measures
19 February 2013
At a recent meeting of the Pharmaceutical Onology Initiative’s (POI) HTA group, OHE’s Nancy Devlin provided an overview of the EuroQol Group’s scientific research agenda for…
EQ-5D Index Clustering: Causes and Implications for Health Care
5 February 2013
In a paper presented at the January 2013 Health Economics Study Group meeting, David Parkin of the NHS and OHE’s Nancy Devlin and Yan Feng examined…